Jeanny B. Aragon‐Ching
YOU?
Author Swipe
View article: Polygenic risk score (PRS) as prostate cancer screening: ready for primetime?
Polygenic risk score (PRS) as prostate cancer screening: ready for primetime? Open
View article: Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy
Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy Open
In the post-FDA approval period, uptake of avelumab 1LM was high (70%) in patients with rwSD or rwCR/PR following 1L PBC, and 41% of these patients received 2L treatment, most commonly with enfortumab vedotin.
View article: Supplementary Table 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Supplementary Table 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Subset of study population showing only gastrointestinal and genitourinary cancer patients
View article: Figure 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Figure 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Percentage of patients in cohort 1 who experienced one or more events by ED diagnosis. Percentage (n) of patients who experienced ≥1 event are displayed for each cancer type. GU, genitourinary; Gyn, gynecologic; Heme, hematologic; H…
View article: Table 3 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Table 3 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Conditional logistic regression models
View article: Table 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Table 2 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
ED diagnoses: summary of cohort 1
View article: Table 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Table 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Baseline patient characteristics and demographics by occurrence of ED visits
View article: Figure 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Figure 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Patient selection flowchart.
View article: Figure 3 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Figure 3 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Comparison of patients with comorbidities between cohorts, percent (n). ORs with 95% CIs are displayed in black for statistically significant comorbidities. The dotted line corresponds to zero patients and an OR of 1. OR not in scal…
View article: Supplementary Table 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Supplementary Table 1 from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
Frequency of events by authorizing provider specialty
View article: Data from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Data from Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
The Centers for Medicare & Medicaid Services Hospital Outpatient Quality Reporting Program’s OP-35 rule penalizes health systems that have a higher-than-expected rate of emergency department (ED) visits or inpatient admissions for 10 poten…
View article: Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities
Real-world Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy-Associated Toxicities Open
The Centers for Medicare & Medicaid Services Hospital Outpatient Quality Reporting Program’s OP-35 rule penalizes health systems that have a higher-than-expected rate of emergency department (ED) visits or inpatient admissions for 10 poten…
View article: The role of circulating tumor DNA (ctDNA) in urothelial cancers
The role of circulating tumor DNA (ctDNA) in urothelial cancers Open
The role of circulating tumor DNA (ctDNA) in urothelial cancers is a rapidly evolving area of research. Urothelial cancer is the most common subtype of bladder cancer, and biomarkers that predict response or prognosticate outcomes have bee…
View article: How to choose duration of additional androgen deprivation therapy with salvage radiation therapy: short, long, more, or none?
How to choose duration of additional androgen deprivation therapy with salvage radiation therapy: short, long, more, or none? Open
View article: Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial Open
View article: The role of perioperative immunotherapy with chemotherapy in muscle-invasive bladder cancer (MIBC)
The role of perioperative immunotherapy with chemotherapy in muscle-invasive bladder cancer (MIBC) Open
View article: Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy
Upper tract urothelial cancer (UTUC) genomic profiling and correlation regarding benefit of platinum-based chemotherapy Open
Upper tract urothelial cancer (UTUC) are rare subsets of urothelial cancer, which typically present with more aggressive course. Molecular markers stratifying urothelial tumors as luminal subtype and non-luminal subtype tumors have been pr…
View article: The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC)
The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC) Open
The landscape of treatment for first-line therapy in advanced urothelial cancer (aUC) and metastatic urothelial cancer (mUC) has rapidly changed in the last year alone. Maintenance avelumab remains a viable treatment option for many patien…
View article: Refining the subgroup analyses and optimal patient population in the JAVELIN Bladder 100 trial
Refining the subgroup analyses and optimal patient population in the JAVELIN Bladder 100 trial Open
View article: Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS Open
Background Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are usually asymptomatic and seek treatments that improve survival but have a low risk of adverse events. Darolutamide, a structurally distinct androgen r…
View article: Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients Open
Purpose of review Patients with biochemically recurrent prostate cancer (BCR) after unsuccessful curative therapies frequently have an indolent and asymptomatic disease course for years. There are no prospective data showing that treating …
View article: The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer
The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer Open
The management of metastatic hormone-sensitive prostate cancer (mHSPC) or castration-sensitive prostate cancer (mCSPC) has become increasingly complex with the tremendous progress that has been made in this space within the past few decade…
View article: Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities
Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities Open
Prostate cancer is the most common non-cutaneous cancer among American men. Multiple mechanisms are involved in tumorigenesis and progression to metastases. While androgen deprivation therapy remains the cornerstone of treatment, progressi…
View article: Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance Open
View article: A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy
A systematic review evaluating the effectiveness of exercise training on physical condition in prostate cancer patients undergoing androgen deprivation therapy Open
Available evidence suggests that exercise training may be used as an adjuvant treatment for PCa patients undergoing ADT to improve several aspects of general health. Studies with more rigorous designs and larger sample sizes are needed to …
View article: Emerging treatment options for prostate cancer
Emerging treatment options for prostate cancer Open
Treatment landscape for metastatic castrate-resistant prostate cancer (mCRPC) has evolved beyond additional agents with ARPI and/or docetaxel, including other treatments with sipuleucel-T, radium, cabazitaxel, PARP inhibitors, and lutetium…
View article: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. C…
View article: Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)
Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC) Open
Approximately a third of patients diagnosed with kidney cancer in the United States present with advanced disease and those who present with distant metastases historically had dismal 5-year relative survival. However, over the last severa…
View article: Rezvilutamide: yet another androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer?
Rezvilutamide: yet another androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer? Open
View article: The role of switch maintenance therapy in urothelial cancers
The role of switch maintenance therapy in urothelial cancers Open
Maintenance therapy with immune checkpoint inhibitors (ICIs) has changed the treatment paradigm of metastatic urothelial carcinoma (mUC). The JAVELIN Bladder 100 trial established avelumab, one of several ICIs in use today, as a life-prolo…